# Slovenia Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Slovenia HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Slovenia (SVN)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $5.2B
- Products: 35
- Buyer markets: 26
- Average CAGR: +27.2%
- Global sector size: $685.3B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $257.2B | $4.3B | $72.0B | +23.8% | 19 | +1.4% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $165.9B | $850.0M | $64.7B | +88.4% | 16 | +0.7% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $22.0B | $729.7K | $29.6B | +32.4% | 3 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $24.8B | $7.0M | $18.3B | +19.3% | 9 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $21.4B | $85.5K | $18.0B | +46.5% | 3 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $26.0B | $22.3M | $15.9B | +21.9% | 8 | +0.1% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $25.3B | $36.6M | $13.5B | +12.8% | 4 | +0.1% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $329.0K | $11.7B | +44.4% | 2 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $2.0M | $10.7B | +28.8% | 3 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $13.4B | $347.3K | $8.5B | +11.8% | 3 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.2B | $841.0K | $8.0B | +4.1% | 4 | +0.0% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $5.1B | $2.1M | $8.0B | -40.0% | 3 | +0.1% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $4.0B | $3.8M | $6.5B | +50.0% | 3 | +0.1% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $2.8M | $6.3B | +30.6% | 3 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $7.8B | $13.5K | $6.3B | -9.1% | 2 | +0.0% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $6.1B | $5.0M | $5.9B | +36.2% | 2 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $6.9B | $621.1K | $5.1B | +2.2% | 2 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $77.2K | $4.1B | +15.4% | 2 | +0.0% |
| HS 290220 - Cyclic hydrocarbons: benzene | $4.1B | $1.5 | $3.5B | -25.4% | 1 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $187.2K | $3.3B | +9.1% | 2 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $4.6B | $126.3K | $2.9B | -6.2% | 2 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $13.5K | $2.1B | +1.0% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $1.5B | $519.7K | $2.1B | +51.7% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $5.5K | $2.0B | +8.5% | 1 | +0.0% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $2.6K | $2.0B | -18.6% | 1 | +0.0% |
| HS 284690 - Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $64.9K | $1.5B | +45.5% | 1 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $1.9B | $2.7 | $1.5B | -34.7% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $16.8 | $1.4B | -13.8% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $36.0K | $1.4B | +40.6% | 1 | +0.0% |
| HS 293722 - Steroidal hormones, their derivatives and structural analogues: halogenated derivatives of corticosteroidal hormones | $1.5B | $0.3 | $1.3B | -34.7% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $3.4M | $1.2B | +29.9% | 1 | +0.2% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $660.2 | $1.1B | -27.5% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $234.7 | $1.1B | +4.9% | 1 | +0.0% |
| HS 293410 - Heterocyclic compounds: containing an unfused thiazole ring (whether or not hydrogenated) in the structure | $890.3M | $30.1K | $1.1B | -14.2% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $2.7B | $508.4K | $1.0B | +34.9% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $117.4B calculated opportunity across 19 products.
- Germany (DEU): $39.0B calculated opportunity across 12 products.
- China (CHN): $29.9B calculated opportunity across 10 products.
- Netherlands (NLD): $20.7B calculated opportunity across 6 products.
- Belgium (BEL): $20.5B calculated opportunity across 4 products.
- Italy (ITA): $12.0B calculated opportunity across 3 products.
- Canada (CAN): $11.8B calculated opportunity across 7 products.
- United Kingdom (GBR): $10.5B calculated opportunity across 5 products.
- Mexico (MEX): $10.2B calculated opportunity across 5 products.
- Switzerland, Liechtenstein (CHE): $9.1B calculated opportunity across 4 products.
- Spain (ESP): $8.9B calculated opportunity across 4 products.
- Japan (JPN): $7.0B calculated opportunity across 2 products.

## Growth stars

- HS 300215: +88.4% average CAGR, $64.7B calculated opportunity.
- HS 290919: +51.7% average CAGR, $2.1B calculated opportunity.
- HS 284190: +50.0% average CAGR, $6.5B calculated opportunity.
- HS 300220: +46.5% average CAGR, $18.0B calculated opportunity.
- HS 284690: +45.5% average CAGR, $1.5B calculated opportunity.
- HS 293359: +44.4% average CAGR, $11.7B calculated opportunity.
- HS 340220: +40.6% average CAGR, $1.4B calculated opportunity.
- HS 293379: +36.2% average CAGR, $5.9B calculated opportunity.
- HS 300290: +34.9% average CAGR, $1.0B calculated opportunity.
- HS 300214: +32.4% average CAGR, $29.6B calculated opportunity.

## Diversification opportunities

- HS 300490: 19 buyer markets, $72.0B calculated opportunity.
- HS 300215: 16 buyer markets, $64.7B calculated opportunity.
- HS 382499: 9 buyer markets, $18.3B calculated opportunity.
- HS 300439: 8 buyer markets, $15.9B calculated opportunity.
- HS 300212: 4 buyer markets, $13.5B calculated opportunity.
- HS 330499: 4 buyer markets, $8.0B calculated opportunity.
- HS 300214: 3 buyer markets, $29.6B calculated opportunity.
- HS 300220: 3 buyer markets, $18.0B calculated opportunity.
- HS 330210: 3 buyer markets, $10.7B calculated opportunity.
- HS 293499: 3 buyer markets, $8.5B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.